ChemGenex raises $12.9m
Wednesday, 17 September, 2008
ChemGenex [ASX: CXS] has completed a $12.9 million capital raising through a share placement to institutional investors.
15.2 million shares were sold at $0.85 per share. Over half of these shares were purchased by existing major ChemGenex shareholders.
The company is also offering existing Australian shareholders the ability to participate on the same terms.
Existing major shareholders Alta Partners, GBS Venture Partners and Merck Snate committed $6.5 million.
The funds will be used for ChemGenex’s clinical trial program of its lead drug candidate, omacetaxine, for chronic myeloid leukaemia.
AusBiotech partners with Tenmile
Designed to support Australia's homegrown life sciences innovation, AusBiotech has announced...
Australian CDC issues update in wake of Ebola outbreak
After the WHO determined the outbreak of Ebola in the DRC and Uganda to be a public health...
Australia announces $7.2m diphtheria outbreak response package
To respond to the biggest diphtheria outbreak on record, support has been announced for the NT...
